A detailed history of Virtus ETF Advisers LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 4,228 shares of CGEM stock, worth $58,600. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,228
Previous 4,153 1.81%
Holding current value
$58,600
Previous $72,000 2.78%
% of portfolio
0.03%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.03 - $20.86 $1,202 - $1,564
75 Added 1.81%
4,228 $70,000
Q2 2024

Aug 14, 2024

SELL
$15.63 - $29.35 $94,217 - $176,921
-6,028 Reduced 59.21%
4,153 $72,000
Q1 2024

May 15, 2024

SELL
$10.17 - $19.02 $7,098 - $13,275
-698 Reduced 6.42%
10,181 $173,000
Q4 2023

Feb 15, 2024

BUY
$7.89 - $10.23 $19,527 - $25,319
2,475 Added 29.45%
10,879 $110,000
Q3 2023

Nov 07, 2023

SELL
$9.05 - $11.72 $7,556 - $9,786
-835 Reduced 9.04%
8,404 $76,000
Q2 2023

Aug 14, 2023

BUY
$8.8 - $13.4 $6,652 - $10,130
756 Added 8.91%
9,239 $99,000
Q1 2023

May 15, 2023

SELL
$10.2 - $11.91 $33,333 - $38,921
-3,268 Reduced 27.81%
8,483 $86,000
Q4 2022

Feb 14, 2023

BUY
$9.72 - $13.62 $29,791 - $41,745
3,065 Added 35.29%
11,751 $123,000
Q3 2022

Nov 14, 2022

BUY
$11.82 - $15.42 $780 - $1,017
66 Added 0.77%
8,686 $111,000
Q2 2022

Aug 12, 2022

SELL
$7.31 - $13.55 $9,656 - $17,899
-1,321 Reduced 13.29%
8,620 $111,000
Q1 2022

May 16, 2022

SELL
$10.47 - $16.75 $6,229 - $9,966
-595 Reduced 5.65%
9,941 $104,000
Q4 2021

Feb 14, 2022

BUY
$15.36 - $25.0 $55,464 - $90,275
3,611 Added 52.14%
10,536 $163,000
Q3 2021

Nov 15, 2021

SELL
$22.56 - $29.68 $8,031 - $10,566
-356 Reduced 4.89%
6,925 $156,000
Q2 2021

Aug 10, 2021

BUY
$24.96 - $41.25 $181,733 - $300,341
7,281 New
7,281 $187,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $632M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.